Evidence map›Paper›PMID 37835599›Full record

ArticleCancers2023

Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond.

Taja Lozar, Israa Laklouk, Athena E Golfinos, Niki Gavrielatou, Jin Xu, Christopher Flynn, Aysenur Keske, Menggang Yu, Justine Y Bruce, Wei Wang and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Cancer therapy resistance from a spatial-omics perspective.Clinical and translational medicine · 2025
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Taja LozarMcArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, 6459 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.ORCID 0000-0003-2893-5580
Israa LakloukDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, MC 8550, 600 Highland Ave, Madison, WI 53792, USA.ORCID 0000-0001-9688-3167
Athena E GolfinosMcArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, 6459 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.ORCID 0000-0002-8365-1743
Niki GavrielatouDepartment of Pathology, Yale University, New Haven, CT 06510, USA.ORCID 0000-0003-1380-6831
Jin XuDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, MC 8550, 600 Highland Ave, Madison, WI 53792, USA.
Christopher FlynnDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, MC 8550, 600 Highland Ave, Madison, WI 53792, USA.
Aysenur KeskeDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, MC 8550, 600 Highland Ave, Madison, WI 53792, USA.
Menggang YuDepartment of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA.
Justine Y BruceUniversity of Wisconsin Carbone Cancer Center, Madison, 53705 WI, USA.
Wei WangMcArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, 6459 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.
Cvetka Grasic KuharUniversity of Ljubljana, 1000 Ljubljana, Slovenia.ORCID 0000-0001-5047-4034
Howard H BaileyUniversity of Wisconsin Carbone Cancer Center, Madison, 53705 WI, USA.
Paul M HarariUniversity of Wisconsin Carbone Cancer Center, Madison, 53705 WI, USA.
Huy Q DinhMcArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, 6459 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.ORCID 0000-0002-3307-1126
David L RimmDepartment of Pathology, Yale University, New Haven, CT 06510, USA.ORCID 0000-0001-5820-4397
Rong HuDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, MC 8550, 600 Highland Ave, Madison, WI 53792, USA.
Paul F LambertMcArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, 6459 Wisconsin Institute for Medical Research, 1111 Highland Ave., Madison, WI 53705, USA.ORCID 0000-0001-7983-2755
Megan B FitzpatrickDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, MC 8550, 600 Highland Ave, Madison, WI 53792, USA.
University of Wisconsin–Madison · USUniversity of Ljubljana · SIYale University · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Visualizing EBV and HCMV DNA Dynamics During InfectionP01CA022443 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI WILLIAM M. SUGDEN · 1985 to 2026
$53.1M
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Zachary Scott Morris · 2022 to 2026
$12.5M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8M
Defining Drivers of HPV-associated CarcinogenesisR35CA210807 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Paul F. Lambert · 2017 to 2026
$9.2M
Mouse Model of Human Papillomavirus PathogenesisR01CA228543 · NCI · TUFTS UNIVERSITY BOSTON · PI LAMBERT, PAUL F., MUNGER, KARL · 2019 to 2023
$2.3M
Automated Tissue MicroarrayerS10OD023526 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MATKOWSKYJ, KRISTINA A. · 2018 to 2018
$184k
NCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA022443NCI NIH HHS P30 CA014520NCI NIH HHS P50 CA278595NCI NIH HHS R01 CA228543NCI NIH HHS R35 CA210807NIDCR NIH HHS P50 DE026787NIH HHS P30CA014520-49NIH HHS S10 OD023526
6 · The paper itself

Abstract

Low response rates in immune check-point blockade (ICB)-treated head and neck squamous cell carcinoma (HNSCC) drive a critical need for robust, clinically validated predictive biomarkers. Our group previously showed that stress keratin 17 (CK17) suppresses macrophage-mediated CXCL9/CXCL10 chemokine signaling involved in attracting activated CD8+ T cells into tumors, correlating with decreased response rate to pembrolizumab-based therapy in a pilot cohort of ICB-treated HNSCC (

Indexed as

biomarker validationcytokeratin 17head and neck cancerimmune check-point inhibitorspembrolizumabpredictive biomarkerspatial transcriptomicsstress keratin 17

Identifiers

PMID37835599
PMCPMC10571921
OpenAlexW4387450498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.